Third, including a control group of non-ARDS patients may have provided interesting information regarding the role of endocan as a diagnostic biomarker, but our aim was to determine whether endocan could be used as an early biomarker of severity in patients already diagnosed with ARDS. This evidence concerns the gene ESM1 and acute respiratory distress syndrome.